| [1] |
Fervenza FC, Hou FF, Hao CM, et al. Obinutuzumab or tacrolimus in primary membranous nephropathy[J/OL]. N Engl J Med (2026-01-05) [2026-07-08]. https://www.nejm.org/doi/10.1056/NEJMoa2602678.
|
| [2] |
陈独群, 涂远茂, 李辉, 等. 奥妥珠单抗治疗难治及高危磷脂酶A2受体相关膜性肾病的疗效观察[J]. 肾脏病与透析肾移植杂志, 2025, 34(1): 1-7.
|
|
Chen DQ, Tu YM, Li H, et al. Obinutuzumab in treatment of high risk or refractory phospholipase A2 receptor associated membranous nephropathy[J]. Chin J Nephrol Dial Transplant, 2025, 34(1): 1-7.
|
| [3] |
Hu X, Zhang M, Xu J, et al. Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy[J]. Clin J Am Soc Nephrol, 2024, 19(12): 1594-1602.
doi: 10.2215/CJN.0000000000000555
|
| [4] |
Xu M, Wang Y, Wu M, et al. Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy[J]. Nephrol Dial Transplant, 2025, 40(5): 978-986.
doi: 10.1093/ndt/gfae230
|
| [5] |
陈独群, 王晶晶, 邱丹丹, 等. 奥妥珠单抗治疗极高危磷脂酶A2受体相关膜性肾病患者的疗效观察[J]. 肾脏病与透析肾移植杂志, 2026, 35(2): 101-106.
|
|
Chen DQ, Wang JJ, Qiu DD, et al. Obinutuzumab in the treatment of phospholipase A2 receptor associated membranous nephropathy with very high risk: an observational study[J]. Chin J Nephrol Dial Transplant, 2026, 35(2): 101-106.
|
| [6] |
Cui Z, Wei M, Li P, et al. Efficacy and safety of MIL62, a Glycoengineered Type Ⅱ Anti-CD20 antibody, in primary membranous nephropathy:a phase 3, randomized, controlled trial [C/OL]. (2025-11-08)[2026-07-08]. https://www.asn-online.org/education/kidneyweek/2025/program-abstract.aspx?controlId=4401259.
|
| [7] |
Lurie A, Daneii P, Khan S, et al. Obinutuzumab versus rituximab for the treatment of primary membranous nephropathy: a systematic review and meta-analysis[J]. Life (Basel), 2026, 16(3): 434.
doi: 10.3390/life16030434
|
)
